AR and prostate carcinoma: Furthermore, considering prostate cancer cells with neuroendocrine features, AR-negative phenotypes are cumulatively found in 36% of patients and 31% of metastatic tumors [203], a strong indication of the importance of cancer cells lacking the AR in advanced disease stages [162,163,164,204].